Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2025 | June 05, 2025 |
| PFIZER INCPFE · Entity 2863 | Director | April 23, 2015 | April 24, 2015 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 03, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,886,576 |
Reported balance
After 2025-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 6,037 · Balance 1,886,576 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,037 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.93 · Expires 2035-06-03 | Direct | 18,111 |
Reported balance
After 2025-06-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-03 · Grant · Acquired 18,111 · Balance 18,111 F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 1 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 78,848 F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 2 | 79,173 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 79,173 F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 3 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 78,848 F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,037 unvested RSUs.
F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
PFIZER INC
Report date April 23, 2015 · Filed April 24, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,099.964 |
Reported balance
After 2015-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2015-04-23 · Grant · Acquired 4,595.588 · Balance 29,099.964 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,434 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 165 · Balance 2,434 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $725.89 · Expires 2033-01-03 | Direct | 1,929 |
Reported balance
After 2023-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-03 · Grant · Acquired 1,929 · Balance 1,929 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2025 Filed Jun 5, 2025 20:23 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 18,111 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0001714899-25-000136 · wk-form4_1749154932.xml · derivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 18,111 shares Expires 2035-06-03 F6 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:23 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000136 · wk-form4_1749154932.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,886,576 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,037 unvested RSUs. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:31 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,901 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001714899-24-000140 · wk-form4_1717540308.xml · derivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2034-05-31 F6 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:31 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000140 · wk-form4_1717540308.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,880,539 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,967 unvested RSUs. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0001714899-23-000099 · wk-form4_1686002790.xml · derivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F6 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-23-000099 · wk-form4_1686002790.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,874,572 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 4,216 unvested RSUs. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000015 · edgardoc.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000015 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,434 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000014 · edgardoc.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000014 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,434 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 00:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 20,000 | $30.48 | $609,600.00 |
DisclosureSEC source: 0001714899-22-000148 · wf-form4_166968178535428.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870,356 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.15 to $31.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 21:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 11,252 | $30.33 | $341,273.16 |
DisclosureSEC source: 0001714899-22-000146 · wf-form4_166751143725460.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890,356 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,748 | $30.20 | $264,189.60 |
DisclosureSEC source: 0001714899-22-000146 · wf-form4_166751143725460.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,901,608 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,612 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · derivative · entry 20 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,612 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,612 | $718.00 | $2,593,416.00 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 17 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,612 | $413.33 | $1,492,947.96 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 16 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,428 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · derivative · entry 19 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,612 Underlying: Common Stock · 3,428 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,428 | $698.00 | $2,392,744.00 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 15 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,428 | $413.33 | $1,416,895.24 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 14 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,798 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · derivative · entry 18 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,040 Underlying: Common Stock · 3,798 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $704.83 | $14,096.60 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 13 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $702.36 | $11,237.76 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 12 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,289 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 80 | $699.82 | $55,985.60 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 11 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,305 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 208 | $698.44 | $145,275.52 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 10 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 208 shares of Company stock on September 29, 2022 at prices ranging from $698.19 to $698.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 160 | $697.29 | $111,566.40 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 9 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 160 shares of Company stock on September 29, 2022 at prices ranging from $697.10 to $697.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 85 | $696.13 | $59,171.05 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 8 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,753 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 85 shares of Company stock on September 29, 2022 at prices ranging from $696.03 to $696.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 554 | $691.59 | $383,140.86 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,838 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 554 shares of Company stock on September 29, 2022 at prices ranging from $691.29 to $691.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 692 | $690.65 | $477,929.80 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,392 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 692 shares of Company stock on September 29, 2022 at prices ranging from $690.06 to $690.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,009 | $689.56 | $695,766.04 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,009 shares of Company stock on September 29, 2022 at prices ranging from $689.07 to $689.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 637 | $688.71 | $438,708.27 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,093 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 637 shares of Company stock on September 29, 2022 at prices ranging from $688.08 to $688.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 321 | $687.90 | $220,815.90 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,730 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 321 shares of Company stock on September 29, 2022 at prices ranging from $687.05 to $687.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $686.89 | $10,990.24 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,051 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 16 shares of Company stock on September 29, 2022 at prices ranging from $686.89 to $686.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,798 | $413.33 | $1,569,827.34 |
DisclosureSEC source: 0001883850-22-000072 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,423 | $31.08 | $137,466.84 |
DisclosureSEC source: 0001714899-22-000133 · wf-form4_166457103687475.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,910,356 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.00 to $31.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 15,577 | $30.74 | $478,836.98 |
DisclosureSEC source: 0001714899-22-000133 · wf-form4_166457103687475.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,914,779 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 22:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 100 | $32.43 | $3,243.00 |
DisclosureSEC source: 0001714899-22-000131 · wf-form4_166146545134466.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,356 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 22:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 19,900 | $31.61 | $629,039.00 |
DisclosureSEC source: 0001714899-22-000131 · wf-form4_166146545134466.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,456 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.33 to $32.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 200 | $36.15 | $7,230.00 |
DisclosureSEC source: 0001714899-22-000109 · wf-form4_165896213456047.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950,356 F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.03 to $36.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 19,800 | $35.60 | $704,880.00 |
DisclosureSEC source: 0001714899-22-000109 · wf-form4_165896213456047.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950,556 F1 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $35.02 to $36.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 00:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Disposition to issuerCommon Stock | 6,766 | $31.08 | $210,260.89 |
DisclosureSEC source: 0001628280-22-018113 · wf-form4_165637764875845.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,970,356 F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.00 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 00:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Disposition to issuerCommon Stock | 39,984 | $30.53 | $1,220,707.52 |
DisclosureSEC source: 0001628280-22-018113 · wf-form4_165637764875845.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,977,122 F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| June 23, 2022 Filed Jun 28, 2022 00:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Disposition to issuerCommon Stock | 13,250 | $31.10 | $412,076.33 |
DisclosureSEC source: 0001628280-22-018113 · wf-form4_165637764875845.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,017,106 F1 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,959 | $0.00 Strike: $24.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000096 · wf-form4_165456054624289.xml · derivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock · 17,959 shares Expires 2032-06-02 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000096 · wf-form4_165456054624289.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,030,356 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 11,598 | $34.14 | $395,955.72 |
DisclosureSEC source: 0001714899-22-000061 · wf-form4_164824543669895.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,024,370 F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,402 | $33.40 | $280,626.80 |
DisclosureSEC source: 0001714899-22-000061 · wf-form4_164824543669895.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,035,968 F1 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| March 23, 2022 Filed Jun 28, 2022 19:07 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 11,598 | $34.14 | $395,955.72 |
DisclosureSEC source: 0001714899-22-000101 · wf-form4a_165644324155351.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,024,370 F1 · date: For this amended Form 4 filing the only change is to add the signature. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| March 23, 2022 Filed Jun 28, 2022 19:07 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,402 | $33.40 | $280,626.80 |
DisclosureSEC source: 0001714899-22-000101 · wf-form4a_165644324155351.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,035,968 F1 · date: For this amended Form 4 filing the only change is to add the signature. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-22-000027 · edgardoc.xml · derivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,439 | $690.00 | $5,132,910.00 |
DisclosureSEC source: 0001708138-22-000027 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.